Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409[G] allele was significantly correlated with severe steatosis (P = 0.04), severe fibrosis at the time of enrollment (P = 0.0005) and fibrosis progression with an OR of 10.31 (95% CI 1.06 - 99.59, P = 0.04), after a mean follow-up time of 62.85 (95%CI: 52.21 - 76.15) months.
|
31642820 |
2019 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 minor allele c.444G represents a risk factor for liver steatosis and fibrosis progression also in chronic hepatitis C (HCV).
|
31527889 |
2019 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The presence of the TM6SF2 c.499A allele in the donor (p=0.014), the PNPLA3 c.444G allele in the donor (p<0.001), posttransplant BMI (p<0.001) and serum triglycerides (p=0.047) independently predicted increased liver fat content on multivariable analysis whereas noncirrhotic liver disease as an indication for liver transplantation was associated with lower risk of steatosis (p=0.003).
|
31356578 |
2020 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Age-related skeletal muscle loss and patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphisms are both associated with increased liver steatosis and fibrosis in the absence of obesity.
|
31250467 |
2019 |
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overall, one-third of HIV/HCV-coinfected patients are affected by HS with PI-based ART and PNPLA3 impacting on HS prevalence.
|
31067123 |
2019 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Studies have shown that two polymorphisms were associated with steatosis and progression of non-alcoholic fatty liver disease (NAFLD) in different populations: the Patatin-like Phospholipase Domain Containing 3 (PNPLA3) and Transmembrane 6 Superfamily Member 2 (TM6SF2).
|
31054980 |
2020 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to confirm the association of the transmembrane 6 superfamily member 2 (TM6SF2) E167K variant with non-alcoholic fatty liver disease (NAFLD) and the degree of steatosis, as well as the additive effect of body mass index (BMI) or the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M and TM6SF2 E167K variants in NAFLD.
|
31054977 |
2020 |
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Taken together, our results show that the steatosis associated with PNPLA3(148M) is caused by accumulation of PNPLA3 on LDs.
|
31019090 |
2019 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We assessed the familial correlation of PRO-C3 concentration, the shared gene effects between PRO-C3 concentration and liver steatosis and fibrosis, and the association between PRO-C3 concentration and genetic variants in the patatin-like phospholipase domain-containing 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), membrane-bound O-acyltransferase domain-containing (MBOAT), and glucokinase regulator (CGKR) genes.
|
30859582 |
2019 |
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Conclusion: Taken together, these findings are consistent with a model in which PNPLA3(148M) promotes steatosis by CGI-58-dependent inhibition of ATGL on LDs.
|
30802989 |
2019 |
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
ASO-mediated silencing of Pnpla3 reduced liver steatosis (p = 0.038) in homozygous Pnpla3 148M/M knock-in mutant mice but not in wild-type littermates fed a steatogenic high-sucrose diet.
|
30772256 |
2019 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Meta-analysis showed that PNPLA3 rs738409 polymorphism exerted strong influence not only on fatty liver but also on the histological injury.
|
30762732 |
2019 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In patients without, but not in those with NASH, significant fibrosis was associated with steatosis grade and the PNPLA3 I148M variant.
|
30708111 |
2019 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3 GG genotype interacted with changes in body weight to aggravate liver steatosis but reduced the risk of incident type 2 diabetes in metabolically unhealthy participants.
|
30673802 |
2019 |
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
PNPLA3 was associated with a portal pattern of steatosis, inflammation and fibrosis.
|
30444569 |
2019 |
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Based on a large monocentric cohort of Caucasian heavy drinkers we could recently provide evidence that PNPLA3 GG primarily correlated with signs of liver damage (steatohepatitis, ballooning) but less with steatosis.
|
30362098 |
2019 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Since DAG (FA18:1) has been implicated in hepatic insulin resistance, the unaltered proportion of DAG (FA18:1) in I148M PNPLA3 carriers with fatty liver may explain the normal insulin sensitivity in these subjects.
|
30227635 |
2018 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to evaluate the role of PNPLA3 rs738409 in the development of MS and HS in CD patients after starting GFD.
|
30189691 |
2018 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The mechanism of how patatin-like phospholipase domain-containing protein 3 (PNPLA3) variant M148 is associated with increased risk of development of hepatic steatosis is still debated.
|
30171718 |
2019 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Establishment and characterization of an iPSC line from a 58 years old high grade patient with nonalcoholic fatty liver disease (70% steatosis) with homozygous wildtype PNPLA3 genotype.
|
30081348 |
2018 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Establishment and characterization of an iPSC line from a 35 years old high grade patient with nonalcoholic fatty liver disease (30-40% steatosis) with homozygous wildtype PNPLA3 genotype.
|
30071394 |
2018 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The presence of the minor PNPLA3 p.I148M risk allele increased the risk of developing NAFLD (OR = 3.29, P < 0.001) and was associated with higher steatosis, fibrosis, and serum CK18-M30 levels (all P < 0.05).
|
29483677 |
2018 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that the liver expression of the PNPLA3 p.148M variant confers a genetic predisposition to liver graft steatosis along with nutritional status and diabetes.
|
29396131 |
2018 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers.
|
29385134 |
2018 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Because PNPLA3 rs738409, GCKR rs780094 and TM6SF2 rs58542926 variants are known to confer susceptibility to NAFLD, we assessed the influence of MBOAT7 rs641738 on hepatic steatosis, and serum levels of CK-18 fragment (a biomarker of hepatocellular injury and apoptosis for NAFLD) after adjusting the effects of PNPLA3, GCKR and TM6SF2 polymorphisms.
|
29314568 |
2018 |